Printer Friendly

Orally Inhaled Corticosteroids to 2022.

LONDON, Sept. 7, 2015 /PRNewswire/ --

Asthma continues to be a health segment that presents challenges to the caregiver community. Patient adherence with prescribing instructions and treatment protocols remains sub-optimal across all patient categories, but particularly for the young and the elderly. This has led to significant interest on the part of device and combination product providers directed toward the development easier-to-use inhalers. Because they reduce inflammation and swelling in the airways, orally inhaled corticosteroids are an indispensable tool for the treatment of asthma. The market entry of combination drug inhalers that deliver a corticosteroid and a bronchodilator from the same inhaler are providing important options for both clinicians and patients.


* Analyzes the market for corticosteroid drugs delivered via oral inhalers

* Assesses inhalation device technology for delivering corticosteroids orally, and evaluates product technology issues and evolving market factors

* Provides detailed assessments of orally inhaled corticosteroid product segments, growth prospects and market potential

* Provides market data and forecasts for orally inhaled corticosteroid drugs to 2022

* Profiles inhaled drug product market participants, their technology, product development activity, and business strategies

* Evaluates the impact of economic, technology, and regulatory factors on inhaled drug companies and their alliance partners

Executive Summary

Orally Inhaled Corticosteroid Market Overview

The Asthma Therapeutics Marketspace

Competing Drug Treatments

Corticosteroids and Asthma

Demand Drivers

Technology Factors

Competitive Landscape

Asthma Market Risks and Opportunities

Global Patient Demographics

Regional Market Drivers

Pediatric Asthma -the Growing Therapeutic Need

Inhaler Technologies for Delivering Corticosteroids

Dry Powder Inhalers

DPI Formulation Technology

Characteristics and Parameters

DPI Excipients and Packaging

Metered Dose Inhalers

MDI Device Selection Criteria

Ease-of-Use Factors


Inhaled Corticosteroids - Product Analysis, Market Data & Forecasts

Beclomethasone, QVAR 40/80 (MDI)

Budesonide, Pulmicort (DPI)

Budesonide, Pulmicort (Nebulizer)

Generic Budesonide (Nebulizer)

Budesonide/Formoterol (Symbicort) Combination Drug Inhaler (MDI)

Ciclesonide, Alvesco (MDI)

Ciclesonide, Zetonna (MDI)

Flunisolide, Aerospan HFA (MDI)

Fluticasone, Arnuity Ellipta (DPI)

Fluticasone, Flovent HFA (MDI)

Fluticasone, Flovent Diskus50/100/250 (DPI)

Fluticasone/Salmeterol (Advair HFA) Combination Drug Inhaler (MDI)

Fluticasone/Salmeterol (Advair Diskus) Combination Drug Inhaler (DPI)

Fluticasone/Vilanterol (Breo Ellipta) Combination Drug Inhaler (DPI)

Mometasone, Asmanex HFA (MDI)

Mometasone, Asmanex Twisthaler (DPI)

Umeclidinium, Incruse Ellipta (DPI)

Umeclidinium/Vilanterol (Anora Ellipta) Combination Drug Inhaler (DPI)

Market Factors

Regulatory Issues

Patient Compliance

Prescribing Trends

Healthcare Economics

Regional Market Factors

Connected Devices

Market Sector Company Profiles

Download the full report:

About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers For more information: Sarah Smith Research Advisor at Email: Tel: +44 208 816 85 48 Website:

To view the original version on PR Newswire, visit:

SOURCE ReportBuyer
COPYRIGHT 2015 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 7, 2015
Previous Article:Global Osteoporosis Partnering 2010-2015.
Next Article:Global Human Insulin Market 2015-2019.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters